Search results
Results from the WOW.Com Content Network
No such effect was seen with another drug of this class, nateglinide. [ 3 ] A 2020 Cochrane systematic review did not find enough evidence of reduction of all-cause mortality, serious adverse events, cardiovascular mortality, non-fatal myocardial infarction , non-fatal stroke or end-stage renal disease when comparing metformin monotherapy to ...
Repaglinide is an antidiabetic drug in the class of medications known as meglitinides, and was invented in 1983. Repaglinide is a medication used in addition to diet and exercise for blood sugar control in type 2 diabetes. [ 1 ]
Glimepiride is an antidiabetic medication within the sulfonylurea class, primarily prescribed for the management of type 2 diabetes. [ 1 ] [ 2 ] It is regarded as a second-line option compared to metformin , due to metformin's well-established safety and efficacy. [ 1 ]
This is the first class of non-opioid pain medication approved to treat moderate to severe acute pain approved by the FDA in more than 20 years. The U.S. Food and Drug Administration (FDA) on ...
Nearly one in three Americans over the age of 60 — roughly 19 million people — take aspirin daily, according to a 2021 study in Annals of Internal Medicine.. Should you be among that group?
A study funded by Novo Nordisk, the U.S. distributor for Repaglinide, compared their product with Nateglinide in "A randomized, parallel-group, open-label, multicenter 16-week clinical trial". [1] They concluded that the two were similar, but "repaglinide monotherapy was significantly more effective than nateglinide monotherapy in reducing ...
ATC code A10 Drugs used in diabetes is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.
Mitiglinide (INN, [1] trade name Glufast) is a drug for the treatment of type 2 diabetes. [2]Mitiglinide belongs to the meglitinide (glinide) class of blood glucose-lowering drugs and is currently co-marketed in Japan by Kissei and Takeda.